Browse articles from EyeWorld.org related to dry eye. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves nasal spray for dry eye ➤ Survey: 70% of adults don’t plan on receiving an eye exam this year ➤ Positive results in Phase 3 study for Acanthamoeba keratitis treatment ➤ Research on first-in-class therapy for retinal degenerative disease ➤ ASCRS news and events
➤ Positive topline results from Phase 3 trial for first-in-class dry eye drop ➤ Study: Long-term efficacy of neuromyelitis optica spectrum disorder treatment ➤ Long-term data from gene therapy injection for wet AMD ➤ Positive data from Phase 1/2 trial of gene therapy for geographic atrophy ➤ Ophthalmic device company partners with augmented reality tech company
➤ Patient enrollment complete for Phase 2 trial of DED drug candidate ➤ New investigational drug candidates for cornea, glaucoma, and wet AMD ➤ IND filed for glaucoma drug candidate ➤ Collaboration for one-time treatment of several retinal conditions ➤ ASCRS news and events
➤ Phase 2 results for cream to treat signs, symptoms of dry eye associated with MGD ➤ Studies support clinical value of ultra-widefield and SS-OCT imaging device ➤ New combination treatment shows promise for metastatic uveal melanoma ➤ ASCRS news and events
➤ Orphan drug designation granted for retinitis pigmentosa treatment ➤ Licensing agreement for progressive myopia treatment ➤ Study: Gene editing prevents Fuchs in mice ➤ Enrollment complete for Phase 3 program evaluating anti-inflammatory, immunomodulation drug for DED ➤ ASCRS news and events
➤ New visual prosthesis heads to clinical trial ➤ FDA grants Fast Track designation to investigational wet AMD therapy ➤ Patient enrollment complete in Phase 3 trial for investigational, first-in-class eye drop for DED ➤ FDA agrees to pivotal trial design for investigational treatment of geographic atrophy secondary to AMD ➤ ASCRS news and events
➤ FDA approves drops for vernal keratoconjunctivitis ➤ Data from investigational first-in-class dry eye therapy ➤ FDA accepts BLA for Port Delivery System of ranibizumab ➤ Companies enter collaboration to investigate treatments for dry AMD ➤ ASCRS news and events
➤ FDA approves spheric, monofocal IOL ➤ Phase 2/3 study of gene therapy for retinitis pigmentosa does not meet primary endpoint ➤ Study: Compounded cyclosporine drop significantly improves OSDI scores ➤ Subretinal injector receives FDA pre-market approval ➤ Three companies form strategic alliance to develop cell therapies ➤ ASCRS events
➤ FDA approves new presbyopia-correcting IOL ➤ New way to evaluate sickle cell retinopathy ➤ Positive Phase 2a data on novel, topical dry eye disease drug candidate ➤ Second Phase 3 trial initiated for Demodex blepharitis treatment ➤ Large-scale, randomized controlled trial replicated with real-world data set ➤ ASCRS events
➤ FDA grants De Novo authorization for new intense pulsed light device ➤ Post-approval study requirements fulfilled for clear corneal incision sealant ➤ Interim analysis for acute adenoviral conjunctivitis drug ➤ NDA resubmission for injection to treat macular edema associated with uveitis ➤ FDA approves abbreviated NDA for glaucoma drug ➤ Study: Functional and psychosocial impact of Demodex blepharitis ➤ Next ASCRS Journal Club on May 13